NasdaqCM - Delayed Quote • USD
Atossa Therapeutics, Inc. (ATOS)
At close: May 15 at 4:00 PM EDT
After hours: May 15 at 7:53 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 4 |
| Avg. Estimate | -0.06 | -0.06 | -0.25 | -0.29 |
| Low Estimate | -0.07 | -0.07 | -0.27 | -0.35 |
| High Estimate | -0.05 | -0.06 | -0.22 | -0.26 |
| Year Ago EPS | -0.08 | -0.05 | -0.24 | -0.25 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 4 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.06 | -0.07 | -0.06 | -0.07 |
| EPS Actual | -0.08 | -0.05 | -0.09 | -0.05 |
| Difference | -0.02 | 0.02 | -0.03 | 0.02 |
| Surprise % | -33.30% | 28.60% | -50.00% | 28.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.06 | -0.06 | -0.25 | -0.29 |
| 7 Days Ago | -0.07 | -0.07 | -0.27 | -0.29 |
| 30 Days Ago | -0.06 | -0.07 | -0.27 | -0.3 |
| 60 Days Ago | -0.06 | -0.07 | -0.26 | -0.32 |
| 90 Days Ago | -0.06 | -0.07 | -0.26 | -0.32 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | -- |
| Up Last 30 Days | 1 | 1 | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ATOS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 25.00% | -- | -- | 8.30% |
| Next Qtr. | -20.00% | -- | -- | 12.40% |
| Current Year | -4.20% | -- | -- | 5.60% |
| Next Year | -16.00% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.13% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight | 5/14/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 5/13/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/16/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 4/2/2024 |
| Initiated | HC Wainwright & Co.: Buy | 2/12/2024 |
| Initiated | Cantor Fitzgerald: Overweight | 9/8/2023 |
Related Tickers
OCGN Ocugen, Inc.
1.9600
+15.29%
TNXP Tonix Pharmaceuticals Holding Corp.
0.1826
+1.44%
SLS SELLAS Life Sciences Group, Inc.
1.4700
+7.30%
CTXR Citius Pharmaceuticals, Inc.
0.6247
-9.15%
JAGX Jaguar Health, Inc.
0.2551
-7.20%
VXRT Vaxart, Inc.
0.9446
+9.24%
AKBA Akebia Therapeutics, Inc.
1.1800
-4.07%
CADL Candel Therapeutics, Inc.
14.00
+30.84%
RVPH Reviva Pharmaceuticals Holdings, Inc.
1.7100
-6.30%
INO Inovio Pharmaceuticals, Inc.
13.07
+14.45%